These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 17010757)

  • 1. Treatment of gefitinib-associated folliculitis.
    Matheis P; Socinski MA; Burkhart C; Warren S; Thomas NE
    J Am Acad Dermatol; 2006 Oct; 55(4):710-3. PubMed ID: 17010757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse reactions to gefitinib (Iressa): revealing sycosis- and pyoderma gangrenosum-like lesions.
    Sagara R; Kitami A; Nakada T; Iijima M
    Int J Dermatol; 2006 Aug; 45(8):1002-3. PubMed ID: 16911406
    [No Abstract]   [Full Text] [Related]  

  • 3. Acneiform eruption induced by Iressa (gefitinib) tablets used to treat non-small cell lung cancer.
    Warthan MM; Jumper CA; Smith JL
    J Drugs Dermatol; 2004; 3(5):569-70. PubMed ID: 15552613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinib.
    Graves JE; Jones BF; Lind AC; Heffernan MP
    J Am Acad Dermatol; 2006 Aug; 55(2):349-53. PubMed ID: 16844529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erlotinib associated with rosacea-like folliculitis and Malassezia sympodialis.
    Cuétara MS; Aguilar A; Martin L; Aspiroz C; del Palacio A
    Br J Dermatol; 2006 Aug; 155(2):477-9. PubMed ID: 16882195
    [No Abstract]   [Full Text] [Related]  

  • 6. Folliculitis-perifolliculitis related to erlotinib therapy spares previously irradiated skin.
    Acharya J; Lyon C; Bottomley DM
    J Am Acad Dermatol; 2009 Jan; 60(1):154-7. PubMed ID: 19103369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tufted hair folliculitis in a woman treated with lapatinib for breast cancer.
    Ena P; Fadda GM; Ena L; Farris A; Santeufemia DA
    Clin Exp Dermatol; 2008 Nov; 33(6):790-1. PubMed ID: 18627387
    [No Abstract]   [Full Text] [Related]  

  • 8. Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study.
    Jänne PA; Gurubhagavatula S; Yeap BY; Lucca J; Ostler P; Skarin AT; Fidias P; Lynch TJ; Johnson BE
    Lung Cancer; 2004 May; 44(2):221-30. PubMed ID: 15084387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of epidermal growth factor receptor inhibitor-induced acneiform eruption with topical recombinant human epidermal growth factor.
    Shin JU; Park JH; Cho BC; Lee JH
    Dermatology; 2012; 225(2):135-40. PubMed ID: 23006507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Folliculitis decalvans associated with erlotinib.
    Hoekzema R; Drillenburg P
    Clin Exp Dermatol; 2010 Dec; 35(8):916-8. PubMed ID: 20456379
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer.
    Hotta K; Kiura K; Ueoka H; Tabata M; Fujiwara K; Kozuki T; Okada T; Hisamoto A; Tanimoto M
    Lung Cancer; 2004 Nov; 46(2):255-61. PubMed ID: 15474674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gefitinib ("Iressa"): a new therapy for advanced non-small-cell lung cancer.
    Reck M; Gatzemeier U
    Respir Med; 2005 Mar; 99(3):298-307. PubMed ID: 15733505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor.
    Van Doorn R; Kirtschig G; Scheffer E; Stoof TJ; Giaccone G
    Br J Dermatol; 2002 Sep; 147(3):598-601. PubMed ID: 12207609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors.
    Zhao Q; Shentu J; Xu N; Zhou J; Yang G; Yao Y; Tan F; Liu D; Wang Y; Zhou J
    Lung Cancer; 2011 Aug; 73(2):195-202. PubMed ID: 21144613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Follicular rash during therapy with erlotinib (Tarceva).
    Gerdes S; Mrowietz U
    J Dtsch Dermatol Ges; 2006 Oct; 4(10):855-7. PubMed ID: 17010175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme.
    Mu XL; Li LY; Zhang XT; Wang SL; Wang MZ
    BMC Cancer; 2004 Aug; 4():51. PubMed ID: 15318946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
    Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
    Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR inhibitor-associated acneiform folliculitis: assessment and management.
    Duvic M
    Am J Clin Dermatol; 2008; 9(5):285-94. PubMed ID: 18717603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gefitinib (ZD1839, Iressa) in non-small-cell lung cancer: a review of clinical trials from a daily practice perspective.
    Barlési F; Tchouhadjian C; Doddoli C; Villani P; Greillier L; Kleisbauer JP; Thomas P; Astoul P
    Fundam Clin Pharmacol; 2005 Jun; 19(3):385-93. PubMed ID: 15910663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gefitinib, a novel, orally administered agent for the treatment of cancer.
    Ranson M; Wardell S
    J Clin Pharm Ther; 2004 Apr; 29(2):95-103. PubMed ID: 15068398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.